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The collecting duct endothelin (ET) system, involving ET-1
and its two receptors, is involved in the physiologic
regulation of renal sodium (Na), water, and acid excretion.
Based on in vitro studies and experiments using genetically
engineered rodents, the physiology of this system in the
collecting duct is being elucidated. Activation of endothelin B
(ETB) receptors on principal cells causes inhibition of Na
transport through signaling pathways involving src kinase,
MAPK1/2, nitric oxide, and possibly prostaglandin E2 (PGE2).
Principal-cell ETB receptors also cause inhibition of water
transport through protein kinase C–mediated inhibition of
AVP-dependent cAMP accumulation. ETB receptors
expressed on intercalated cells augment acid secretion,
possibly through nitric oxide–dependent mechanisms. The
role of endothelin A (ETA) receptors in the collecting duct
remains unclear; however, recent evidence suggests that
these receptors can exert natriuretic and diuretic effects.
Further complexity is lent to this system by studies indicating
that ETA and ETB receptors can homo- and hetero-dimerize,
with possible functional consequences. This brief review will
describe our current state of knowledge about this complex
regulatory system in the collecting duct, and will identify
clinically relevant issues that need addressing.
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The collecting duct (CD), by virtue of being the final
nephron segment controlling urinary electrolyte and water
content, is one of the major renal sites targeted by circulating
hormones. Although these factors maintain a vital link
between systemic conditions and CD responses, the CD also
contains intrinsic systems for maintaining electrolyte and
water homeostasis. Of these local mechanisms, CD-derived
endothelin-1 (ET-1) and its cognate receptors have emerged
as being of particular importance in the control of renal
sodium (Na), water, and acid excretion. This review will
examine the role of the CD ET system in the modulation of
renal function, emphasizing new developments in our
understanding of the biology of CD ET receptors.
OVERVIEW OF ET BIOLOGY
The ET family consists of three 21-amino acid peptides
(ET-1, ET-2, and ET-3), which are structurally very similar to
the snake venom sarafotoxins.1 ET-1 mRNA encodes a
prepropeptide that is cleaved by furin-like proteases to Big
ET-1 which is, in turn, proteolyzed by ET-converting
enzymes to yield the mature peptide. The kidney contains
at least two ET-degrading enzymes, including a neutral
endopeptidase. Three ET G-protein-coupled receptors have
been described; however, only two have been identified
in mammals: the ETA (endothelin A, ETRA) and ETB
(endothelin B, ETRB) receptors. ETRA binds ET-1X
ET-2bET-3, whereas ETRB binds all ETs with equal affinity.
Alternative RNA splicing of both ETRA2 and ETRB3 can
occur, with alterations in receptor functional characteristics.
However, alternative splicing of renal ET receptors, in terms
of localization or biological consequences, has not been
described.
Antagonists and agonists with apparent high specificity
for ETRA or ETRB have been used to help define ET receptor
isoform function. Despite the large numbers of studies with
these pharmacological agents, unequivocal identification of
individual ET receptor isoform action remains elusive. Part of
this difficulty may relate to ET receptor dimerization.4
Fluorescent resonance energy transfer analysis of ET receptors
expressed in a heterologous system showed the presence of
ETRA and ETRB homodimers.5 More importantly, this
group observed evidence for ETRA–ETRB heterodimerization
based on ligand-dependent differences in receptor internali-
zation.6 Several other studies, using ligand-binding assays or
functional readouts of receptor activation, have also sug-
gested that ETRA and ETRB may interact cooperatively.
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To further complicate the picture, ETRB may heterodimerize
with receptors other than ETRA, including the dopamine
D3 and the angiotensin AT1 receptors.7,8 Whether such ET
receptor heterodimerization occurs in the CD is unknown;
however, as will be seen from the ensuing discussion, such
heterodimerization may indeed occur in the CD and may
explain, at least in part, some puzzling results from in vivo
studies.
CD ET SYNTHESIS AND RECEPTOR EXPRESSION
The CD (particularly the inner medullary CD (IMCD))
produces far more ET-1 than any other cell type in the kidney
and possibly in the entire body.9 CD ET-1 production is
increased during natriuretic or diuretic conditions; the
mechanisms by which this occur are uncertain, but may
include interstitial fluid osmolality, tubule fluid flow rate,
and other factors.9,10
The CD is also the major nephron site of ET receptor
expression. Numerous studies show that the IMCD in
experimental animals and humans express ETRB in relatively
large amounts.9,11 Cortical CD (CCD) ETRB expression is
also present, as determined by PCR of mRNA, immuno-
staining, and examination of the effect of ETRB blockade on
ET-1 actions in the isolated CCD.12–19 In contrast, CD ETRA
expression has been less clear. Autoradiography of whole
kidneys or PCR of nephron segments detected no ETRA
in rat or in human CD.16,20,21 In contrast, immunohisto-
chemical, binding, and PCR studies detected ETRA in the
CD from rats or dogs.22–24 More recent studies, using
immunostaining of the rat kidney, observed CD ETRA
staining.25 In addition, ETRA immunoreactivity was detected
on the basal infoldings and was scattered within the
cytoplasm of the rat CD (particularly in the IMCD).26 As
will be described below, there is also functional evidence for
the existence of CD ETRA. Taken together, the above studies
suggest that the CD does express ETRA, although in
substantially smaller amounts than ETRB.
ET RECEPTORS AND CD Na TRANSPORT AND BP
ET-1 can affect renal Na excretion and blood pressure (BP)
through the regulation of a variety of mechanisms, including
renal blood flow, glomerular filtration rate, and sodium
transport processes throughout the nephron. The CD ET
system has proven to be a particularly important physiolo-
gical regulator of renal Na excretion and systemic BP. Several
in vitro studies suggested that ET-1 inhibits CD Na transport.
ET-1 decreases Na reabsorption in the isolated CCD,27
reduces Na uptake by distal nephron A6 cells,28 and inhibits
Na/K ATPase activity in IMCD cells.29 Recent studies, using
isolated split-open rat CCD, found that ET-1 decreases
epithelial Na channel (ENaC) open probability.12 Direct
evidence that CD-derived ET-1 regulates Na excretion was
provided by studies using CD principal cell-specific knockout
(KO) of the ET-1 gene.30 Mice lacking ET-1 exclusively in the
CD were hypertensive (B18mmHg systolic BP greater than
controls) and, when exposed to high Na intake, had
exacerbated hypertension (B35mmHg systolic BP greater
than controls) associated with a reduced ability to excrete the
Na load. Amiloride reduced the hypertension in CD ET-1 KO
mice, suggesting that the CD was not only the source of ET-1
but may also have been involved in mediating the natriuretic
effects of ET-1.
In vitro studies suggested that the natriuretic effects of
ET-1 on the CD are largely mediated through the activation
of ETRB. In this study, ETRB stimulation inhibited, whereas
ETRA activation increased Na uptake by A6 cells.28 Blockade
of ETRB, but not of ETRA, prevented ET-1 inhibition of
ENaC open probability in the rat CCD.12 Intra-medullary
infusion of an ETRB antagonist reduced urine flow and Na
excretion, an effect that could have been mediated by the
blockade of CD ETRB and/or by reducing medullary blood
flow.31,32 In whole animal studies, rats deficient in ETRB,
which had been rescued from early mortality by a dopamine
b-hydroxylase promoter ETRB transgene, had salt-sensitive
hypertension.33 The hypertension was partially corrected by
amiloride, suggesting that CD ETRB inhibition of ENaC is
involved in maintaining normal BP. More direct evidence for
a role of CD ETRB in modulating BP and Na excretion was
obtained using mice with CD principal cell-specific KO of
ETRB.11 These mice had elevated BP; high Na intake further
increased BP and was associated with decreased elimination
of the Na load. However, the degree of hypertension and Na
retention was approximately one-half of that seen with CD
ET-1 KO mice on a normal or high Na diet, suggesting that
CD ETRB does not mediate all of the anti-hypertensive and
natriuretic effects of CD-derived ET-1.
In vitro studies had found no evidence for CD ETRA
modulation of CD Na transport; however, to examine this
question in vivo, mice with CD principal cell-specific KO of
ETRA were generated.34 As expected, CD ETRA KO had no
effect on BP or urinary Na excretion, either during normal or
high Na intake. Taken together, the CD ET-1 KO, CD ETRA
KO, and ETRB KO findings suggested that CD-derived ET-1
exerted natriuretic and hypotensive effects in part through
the autocrine activation of CD ETB receptors and in part
through the paracrine interaction with cells other than CD
principal cells. To confirm this conclusion, mice were
developed with combined disruption of ETRA and ETRB
in CD principal cells.35 Contrary to expectations, the
magnitude of hypertension and Na retention in CD ETRA/
B KO mice was significantly greater than that in CD ETRB
KO animals. Furthermore, the degree of Na retention and
hypertension in the double ET receptor KO mice was almost
identical to that observed in CD ET-1 KO mice. How can
these findings be reconciled? Although the reason(s) remain
speculative, one possibility relates to ET receptor dimeriza-
tion. As ETRBs are the most abundant isoform in the CD,
then ETRB homodimers and ETRA/B heterodimers may
predominate. In the CD ETRB KO, ETRA homodimers,
which may not normally exist in sufficient amounts, could
potentially exert a natriuretic effect. Although in vitro studies
do not support such a role for ETRA, very recent studies
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suggest that ETRA may, in fact, be natriuretic. Infusion of
ET-1 into the renal medulla of ETRB-deficient rats surpris-
ingly caused a natriuresis that was blocked by the adminis-
tration of an ETRA antagonist.36 This effect was observed
only in female rats; however, ET-1 infusion reduced
medullary blood flow (thereby exerting a counteracting
anti-natriuretic effect) only in male animals. Clearly, more
studies are needed to clarify the role of CD ETRA, although
demonstration of ET receptor dimerization in vivo, and its
functional consequences, will be challenging. It should be
noted that clarification of the role of CD ETRA in regulating
natriuresis may have immediate clinical relevance. Adminis-
tration of ETRA antagonists to humans is associated with a
high incidence of hemodilution and edema formation,
strongly suggestive of renal fluid retention.37 For the renal
community, this issue is of particular importance in that
ETRA antagonism with avosentan caused a substantial
(B50% vs controls) reduction in urinary albumin excretion
in a phase II trial in patients with diabetic nephropathy.38 A
recent phase III trial intended to examine the effect of
avosentan on the doubling of serum creatinine, ESRD or
death in these patients was discontinued due to problems
associated with fluid retention.39
The mechanisms by which CD ET receptors reduce Na
transport have been partially resolved (Figure 1). ET-1
rapidly decreases rat CCD ENaC open channel prob-
ability (within 5min) through ETRB and this effect is
dependent on src kinases and MAPK1/2 (mitogen-activated
protein kinase 1/2) signaling, while being independent of
phospholipase C or protein kinase C.12 Nitric oxide (NO)
also is involved in the natriuretic and hypotensive effects of
ET-1, which, through ETRB activation, stimulates NO
synthase (NOS)1-dependent NO production by cultured rat
IMCD cells.40 ET-1 increased NOS1 protein expression in the
IMCD3 cell line; however, interestingly this was ETRA
dependent.41 Infusion of the ETRB agonist, sarafotoxin S6c,
into the rat renal medulla caused a diuresis and natriuresis
that was suppressed by the inhibition of NOS1 or protein
kinase G.42 Notably, NO blockade increased the BP in control
and in CD ET-1 KO mice to the point at which there was no
BP difference between the two groups, whereas urinary
nitrate/nitrite excretion and activities of NOS1 and NOS3
were substantially lower in CD ET-1 KO animals.43 In the
same study, incremental increases in renal perfusion pressure
were associated with reduced Na and NO metabolite
excretion in CD ET-1 KO mice. Finally, a role for
prostaglandin E2 (PGE2) in mediating ET-1 natriuresis in
the CD was suggested by studies in which COX (cycloox-
ygenase) blockade prevented ET-1 inhibition of Na/K ATPase
activity in the isolated IMCD.29 ET-1 increases IMCD
PGE2 production, and this is carried out through ETRB
activation.29,44 In contrast, COX inhibition in CD ET-1 KO
mice did not affect Na retention or BP, although urinary and
IMCD PGE2 levels were unexpectedly increased.45 This
increase in PGE2 seems to be a compensatory response for
alterations in water metabolism, so it is impossible to rule out
a role for CD PGE2 in the ET-1 natriuretic response. In
summary, CD ETRB activation with resultant increases in the
activity of src kinase, MAPK1/2, NOS1, and possibly COX,
inhibits CD Na transport. CD ETRA activation may increase
NOS1; however, the biological consequences of this remain to
be determined.
ET RECEPTORS AND CD WATER TRANSPORT
There is abundant evidence that the CD ET system modulates
renal water transport. Initial in vitro studies noted that ET-1
inhibited vasopressin (arginine vasopressin, AVP)-stimulated
osmotic water permeability in the CCD and IMCD.27,46 The
physiological role of CD-derived ET-1 in regulating renal
water handling was shown using CD ET-1 KO mice.47 CD
ET-1 KO animals had reduced plasma AVP levels, impaired
ability to excrete an acute water load, and increased urine
concentration in response to exogenous AVP.
The ET receptor subtype in the CD responsible for the
diuretic effects of ET-1 has not been ascertained fully, but is
likely to be, at least in large part, ETRB. ET-1 blockade of
AVP-stimulated osmotic water permeability in acutely
isolated CD is ETRB dependent.27 ET-1 has also been shown
to inhibit AVP-stimulated cyclic adenosine monophosphate
(cAMP) accumulation in the CD; this effect was due to ETRB
activation.18,44 CD ETRA KO mice have decreased respon-
siveness to AVP as evidenced by elevated plasma AVP
levels and an enhanced ability to excrete a water load; this
suggests that CD ETRA may exert an anti-diuretic effect.34
This conclusion is further supported by the finding that the
IMCD isolated from CD ET-1 KO mice had elevated AVP-
stimulated cAMP accumulation, whereas IMCD suspensions
from CD ETRA KO mice had reduced AVP-stimulated cAMP
accumulation. Similar studies on water handling and cAMP
Na+
Na+
K+
PLA2PGE2
COX
ETB
ENaC
SrcNOS1
NO MAPK1/2
_
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_
Figure 1 | Schematic of ET receptor B (ETRB) regulation of the
collecting duct Na transport. COX, cyclooxygenase; ENaC,
epithelial Na channel; MAPK, mitogen-activated protein kinase; NO,
nitric oxide; NOS, nitric oxide synthase; PGE2, prostaglandin E2;
PLA, phospholipase A; Src, src tyrosine kinase.
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production are underway in CD ETRB and in combined CD
ETRA/B KO mice.
The mechanisms by which ET-1 inhibits CD water
transport are partially understood (Figure 2). ETRB-
mediated inhibition of AVP-stimulated cAMP content in
the IMCD is dependent on phospholipase C, diacylglycerol,
and protein kinase C, and likely involves interaction with
adenylyl cyclase isoforms 3 and 6.18,44 ET-1 acts through an
inhibitory G protein as pertussis toxin blocks the ET-1 effect
on AVP-stimulated cAMP accumulation in the IMCD.44 As
ET-1 stimulates CD NO production and as NO can inhibit
AVP-stimulated water permeability and cAMP accumulation
in the rat CCD,48 it would seem likely that NO at least
partially mediates the ET-1 diuretic effect. However, NOS
blockade had no effect on ET-1 inhibition of AVP-stimulated
cAMP content in IMCD suspensions.40 Notably, no effect of
NO donors on AVP-stimulated cAMP levels was detected in
rat IMCD cells. Why different results were obtained in these
studies is unknown; it remains, therefore, an open question
as to whether NO mediates, at least in part, the diuretic
effects of ET-1 in the CD.
ET RECEPTORS AND CD ACID–BASE SECRETION
ET-1 may be involved in enhanced urinary acidification in
response to a systemic acid load.49 Metabolic acidosis
stimulates renal ET-1 production;49 the specific cell types
involved are not known fully. Preliminary studies in our
laboratory found that mice with intercalated cell-specific
KO of ET-1 developed metabolic acidosis, suggesting that
ET-1 derived from this cell type may be involved in
maintaining normal acid secretion (unpublished results).
In addition, ET receptor antagonism reduced luminal
acidification in the isolated CCD (that is, endogenous ET-1
effects were blocked).19 This latter study found that ETRB
blockade prevented the adaptive increase in Hþ secretion by
A-intercalated cells and the decrease in HCO3
 secretion in
B-intercalated cells in response to an acute (3 h) decrease in
luminal and bath pH to 6.8. Furthermore, the adaptive
decrease in HCO3
 secretion, but not that in Hþ secretion,
was prevented by NOS, guanylyl cyclase, or protein kinase G
blockade (Figure 3). Although direct identification of the
relevant signaling pathways is needed, taken together, the
above studies increase the possibility that CD-derived ET-1
acts, possibly through ETRB, on both A- and B-intercalated
cells, and NO in B-intercalated cells, to augment CD luminal
acidification.
ALTERATIONS IN CD ET RECEPTORS IN DISEASE STATES
Relatively little is known about changes in CD ET receptors in
disease states. CD ETRB expression was found to be increased
in rats with compensated congestive heart failure, whereas
CD ETRB expression was substantially downregulated in rats
with decompensated heart failure.50 Although the functional
significance of such changes remains speculative, decreased
CD ETRB might contribute to Na retention in decompen-
sated heart failure. CD ETRA and ETRB expression were not
changed in patients with acute renal transplant rejection
(although distal tubule ETRA labeling was decreased).51
Clearly, more studies are needed on the role of alterations in
CD ET receptors in disease states.
SUMMARY
The ET system is involved in modulating Na and water
reabsorption by CD principal cells, and possibly Hþ and
HCO3
 secretion by CD intercalated cells. CD ETRB appears
to mediate ET-1 inhibition of ENaC, AVP-stimulated water
transport, and acid-induced urinary acidification. Findings in
experimental animals, and in humans treated with ETRA
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_
Figure 2 | Schematic of ET receptor B regulation of the
collecting duct water transport. AC3/6, adenylyl cyclase 3 and 6
isoforms; AQP2, aquaporin-2; AQP2-P, phosphorylated AQP2;
cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol;
PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase
C; V2, vasopressin receptor.
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Figure 3 | Schematic of ET receptor B regulation of the
collecting duct proton and bicarbonate transport. cGMP, cyclic
guanosine monophosphate; GC, guanylyl cyclase; NO, nitric oxide;
NOS, nitric oxide synthase; PKG, cGMP-dependent protein kinase.
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antagonists, suggest that CD ETRA may exert natriuretic and
diuretic effects.
Despite our advances in understanding the CD ET system,
key questions remain to be answered. If the CD ET system is
fundamentally important in fine-tuning renal Na, water and
acid excretion, how can ET-1 production and CD ET receptor
activation be tightly controlled and compartmentalized so
that transport of these substances is individually regulated?
Does ET receptor homodimerization and/or heterodimeriza-
tion occur, how is it regulated, and does such a dimer
configuration exert functional effects? As the clinical use of
ETRAs grows, associated with side effects that may involve
the kidney (fluid retention), the answers to these questions
become increasingly pressing.
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